Artist rendering of AstraZeneca's planned antibody-drug conjugate facility in Singapore. (Credit: AstraZeneca)
May 20, 2024 06:07 AM EDTUpdated 10:02 AM
Manufacturing

As­traZeneca ear­marks $1.5B for end-to-end ADC fac­to­ry in Sin­ga­pore

Anna Brown

News Reporter

As­traZeneca said on Mon­day morn­ing it is build­ing a new an­ti­body-drug con­ju­gate fa­cil­i­ty in Sin­ga­pore worth $1.5 bil­lion.

The UK phar­ma said this will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times